drugset
drugset / Trial / NCT07109869

Safety and Efficacy of Boric Acid Inserts for Treatment of Vulvovaginal Candidiasis

NCT07109869 ↗

Phase 3 Recruiting 400 enrolled pH-D Feminine Health LLC
RandomizedParallel-groupSingle-blindTreatment

Summary

This is a Phase 3 clinical study to evaluate the efficacy, safety, and tolerability of boric acid 600 mg vaginal inserts in patients with VVC.

Timeline

Start
2025-08-08
Primary completion
2026-07
Completion
2026-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Boric acid Small molecule 600 mg Other

Indications

vulvovaginal candidiasis